Benralizumab (Fasenra®) is indicated as add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
NCPE Assessment Process | Complete |
Rapid review commissioned | 15/01/2018 |
Rapid review completed | 14/02/2018 |
Rapid Review outcome | Full pharamcoeconomic assessment recommended at the submitted price |